Latest news with #NeerajAgrawal
Time Business News
3 days ago
- Business
- Time Business News
A2N Advisory Expands Bookkeeping Services for U.S. Businesses, Led by CA Neeraj Agrawal
NOIDA, INDIA – June 26, 2025 – A2N Advisory, a leading financial company co-founded by experienced accountant Neeraj Agrawal, today announced a major push to offer outsourced bookkeeping services to companies in the United States. This big step aims to give U.S. businesses excellent, affordable, and efficient ways to manage their money, using India's skilled workforce. This move comes as more U.S. businesses look to save money and make their financial records more accurate by having experts handle common but important tasks. CA Neeraj Agrawal explained A2N Advisory's goal to help American companies. 'Our expansion into the U.S. market is a direct response to the growing need for reliable and affordable accounting help,' Agrawal said. 'We offer U.S. companies big benefits like significant cost savings, access to many skilled accountants who understand U.S. financial rules (US GAAP), and the chance for their own teams to focus on business growth and future plans.' A2N Advisory uses strong methods to provide great service. The company's team includes highly qualified accounting professionals, like Chartered Accountants, who know a lot about both U.S. and Indian accounting practices. This ensures that when businesses choose to outsource bookkeeping from USA to India with A2N Advisory, they get services that are very accurate and follow all rules. Using the latest technology and keeping data safe are top priorities for A2N Advisory. The company uses modern cloud-based accounting software for easy, real-time access to financial information and smooth communication. Also, strict security measures, like strong data encryption, secure servers, and tight privacy agreements, are in place to protect sensitive client financial details. A2N Advisory has a proven track record of success with its current U.S. clients. While specific client names are kept private, companies have consistently praised A2N Advisory for their careful work and helpful reports. Clients often highlight the firm's 'clear approach and reporting,' which gives them 'valuable insights into their financial health.' A2N Advisory believes this success comes from focusing on the client and acting like a natural extension of their finance department. The expanded services for U.S. businesses include a full range of solutions: Managing bills to pay (accounts payable) and money owed (accounts receivable) Keeping the main accounting records (general ledger maintenance) Matching bank statements (bank reconciliation) Preparing financial reports Helping with payroll Support for tax preparation All these services are carefully customized to fit the specific needs and rules of each client. A2N Advisory's strong focus on the U.S. market shows its role as a global provider of financial advice, dedicated to helping its international clients grow and stay financially stable. TIME BUSINESS NEWS
The Hindu
09-06-2025
- Business
- The Hindu
Advent to invest $175 million in Felix Pharma to acquire minority stake
Advent, a private equity investor, has announced that funds managed by it have signed a definitive agreement to invest $175 million via primary and secondary capital for a significant minority stake in Dublin, Ireland-based Felix Pharmaceuticals Pvt. Ltd. (Felix), a global Gx animal pharma player. Felix Pharma is one of the developers and manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded Gx players for private labelling, particularly in the U.S. Shweta Jalan, Managing Partner, Advent, said, 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx globally and emerging opportunity in animal health Gx. Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities.' 'Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' she added, Founded in 2015 by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, Chair of GSK and with 30 years of experience in global pharmaceuticals, and Dr. Shumeet Banerji, ex-CEO of Booz-Allen, Felix said it has pursued strategic growth through a disciplined approach, While the company achieved its first U.S. FDA approval in 2020, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline. It has a USFDA-approved oral solid facility dedicated to animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder, Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger. Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence.'
Economic Times
09-06-2025
- Business
- Economic Times
Advent International to acquire stake in Felix Pharmaceuticals
Advent International, a leading global private equity investor, signed a definitive agreement to invest $175 million via primary and secondary for a significant minority stake in Dublin-headquartered Felix Pharmaceuticals, a leading global generic animal pharma player, stated a company release. Felix Pharma is a manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded generic players for private labelling, particularly in the US. With a portfolio of 14 approved products from USFDA and many more under review and development, Felix has the widest portfolio of products in the industry. 'Felix is well positioned to lead this generic space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities. Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' said Shweta Jalan, Managing Partner at Advent. Felix was founded in 2015 by Neeraj Agrawal, Sir Jonathan Symonds and Dr Shumeet Banerji, ex-CEO of Booz-Allen. While the company achieved its first US FDA approval in 2020, marking a pivotal step in its expansion, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline, it said. It has a USFDA approved oral solid facility dedicated for animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder of Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger.'
Time of India
09-06-2025
- Business
- Time of India
Advent International to acquire stake in Felix Pharmaceuticals
Advent International , a leading global private equity investor , signed a definitive agreement to invest $175 million via primary and secondary for a significant minority stake in Dublin-headquartered Felix Pharmaceuticals , a leading global generic animal pharma player, stated a company release. Felix Pharma is a manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded generic players for private labelling, particularly in the US. With a portfolio of 14 approved products from USFDA and many more under review and development, Felix has the widest portfolio of products in the industry. 'Felix is well positioned to lead this generic space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities. Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' said Shweta Jalan, Managing Partner at Advent. Felix was founded in 2015 by Neeraj Agrawal, Sir Jonathan Symonds and Dr Shumeet Banerji, ex-CEO of Booz-Allen. While the company achieved its first US FDA approval in 2020, marking a pivotal step in its expansion, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline, it said. It has a USFDA approved oral solid facility dedicated for animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder of Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger.'
Mint
09-06-2025
- Business
- Mint
Advent to acquire significant minority stake in animal drug maker Felix Pharmaceuticals for $175 million
Private equity firm Advent International has signed a definitive agreement to invest $175 million (about ₹ 1,500 crore) for a significant minority stake in Felix Pharmaceuticals Pvt. Ltd, an Ireland-headquartered company focused on developing and manufacturing generic medicines for companion animals such as dogs, cats, and horses. This marks another bet by Advent in the growing healthcare space, this time tapping into the under-penetrated animal health generics segment, where branded drugs continue to dominate. Founded in 2015, Felix Pharma is among the fastest-growing companies in the animal health space, with 14 USFDA-approved products and several more in the pipeline. The company primarily supplies to distributors and other branded generics players, especially in the US, through private labelling. 'Felix has an opportunity to shape the companion animal health generics market. The industry is nascent, with less than 10% share held by generic players, providing a long-term growth opportunity,' said Pankaj Patwari, managing director at Advent, in a statement. 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger,' said Neeraj Agrawal, co-founder of Felix. 'Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence,' he added. Felix was co-founded by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, chair of GSK, and Dr. Shumeet Banerji, former CEO of Booz Allen Hamilton. The company received its first USFDA approval in 2020, and now operates a dedicated R&D centre and a USFDA-approved manufacturing plant for animal health products. The facility includes dedicated oral solids and liquids capabilities tailored specifically for the veterinary generics market. 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx [generics] globally and emerging opportunity in animal health Gx,' said Shweta Jalan, managing partner at Advent. 'Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities,' she said. The deal comes amid a sharp rise in global demand for animal drugs, as pet ownership and spending on pet healthcare rise across geographies. Advent has been actively investing in Indian healthcare and financial services. In April 2024, it acquired a 12.1% stake in Apollo Healthco, a unit of Apollo Hospitals, for ₹ 2,475 crore. Last year, it invested $230 million in Svatantra Microfin along with Multiples PE, and exited Bharat Serums and Vaccines, selling it to Mankind Pharma for ₹ 13,630 crore.
